Search

Roivant Sciences Ltd

Lezárt

SzektorEgészségügy

41 0.44

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

40.36

Maximum

41.58

Fő mutatók

By Trading Economics

Bevétel

-646M

-291M

Értékesítés

-1.1M

1.4M

Egy részvényre jutó nyereség

-0.45

Profit margin

-20,152.982

Munkavállalók

721

EBITDA

-743M

-288M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+11.62% upside

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

1.2B

25B

Előző nyitás

40.56

Előző zárás

41

Hangulat hírek alapján

By Acuity

50%

50%

112 / 339 Rangsor szerint Healthcare

Roivant Sciences Ltd Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 14. 20:13 UTC

Shares of Roivant Sciences are lower in after-market hours, reflecting a notable decline since Monday's close, despite remaining above the 20-day moving average.

2026. szept. 11. 20:13 UTC

Roivant Sciences Ltd. shares are lower in after-market trading, amid broader market concerns over potential Federal Reserve interest rate hikes following recent inflation data.

2026. szept. 10. 23:31 UTC

Roivant Sciences Ltd shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

2026. szept. 9. 23:06 UTC

Roivant Sciences Ltd shares are higher in after-market hours, maintaining a narrow trading range since Wednesday's close and staying above the 20-day moving average.

2026. szept. 8. 23:06 UTC

Event
News

Roivant Sciences Ltd shares are lower in after-market hours despite positive Phase 2 trial results for mosliciguat targeting pulmonary hypertension.

2026. szept. 4. 22:51 UTC

Correlated Moves

Roivant Sciences Ltd shares are lower in after-market trading, reflecting broader market declines and negative sentiment in the biotech sector.

2026. szept. 2. 20:08 UTC

Roivant Sciences Ltd shares are lower today, breaking a trend of higher closes. No specific news was identified to explain the decline.

2026. szept. 1. 19:36 UTC

Roivant Sciences Ltd is trading lower amid broader market sentiment and rising oil prices. The stock remains below its 20-day moving average.

2026. aug. 31. 22:01 UTC

Roivant Sciences Ltd shares are higher in after-hours trading, showing modest gains since Monday's close amid rising oil prices and geopolitical tensions.

2026. aug. 29. 00:01 UTC

Roivant Sciences Ltd shares are higher in after-market hours, reflecting notable activity despite a retracement from earlier gains. No specific news was identified.

2026. aug. 28. 23:01 UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting notable activity following Friday's close, despite no specific news identified.

2026. aug. 27. 23:02 UTC

Roivant Sciences Ltd. shares are higher in after-market trading, remaining above the 20-day moving average despite earlier fluctuations during the session.

2026. aug. 26. 22:41 UTC

Roivant Sciences Ltd is trading higher in after-market hours, reflecting broader market gains. The asset has closed higher for three consecutive sessions.

2026. aug. 25. 23:16 UTC

Roivant Sciences Ltd. shares are lower in after-market trading, continuing a steady decline since Tuesday's close, though still above the 20-day moving average.

2026. aug. 24. 23:01 UTC

Roivant Sciences Ltd. shares are lower in after-market trading, retracing from an earlier session high while remaining above the 20-day moving average.

2026. aug. 21. 19:31 UTC

Roivant Sciences is declining in Friday's session, with no specific news identified. The stock has seen unusually high trading volume today.

2026. aug. 20. 23:21 UTC

Roivant Sciences Ltd. shares are lower in after-market trading amid broader market pressures, including rising bond yields and concerns over high borrowing costs.

2026. aug. 19. 23:26 UTC

Roivant Sciences Ltd is seeing upward momentum in after-market trading, recovering from a prior dip and nearing the upper end of its one-month trading range.

2026. aug. 18. 23:01 UTC

Roivant Sciences Ltd shares are lower in after-market trading, declining notably after Tuesday's close amid rising U.S. Treasury yields and inflation concerns.

2026. aug. 17. 19:36 UTC

Roivant Sciences shares are roughly flat amid broader market declines. The bond market faces upward pressure on yields due to inflation concerns.

2026. aug. 14. 19:26 UTC

Roivant Sciences Ltd. remains near unchanged amid no specific news, fluctuating around flat levels during Friday's session. It is 4.29% above its 20-day moving average.

2026. aug. 13. 19:36 UTC

Roivant Sciences Ltd is trading modestly higher amid broader market dynamics. Initial jobless claims rose above expectations, indicating potential softness in the labor market.

2026. aug. 12. 22:11 UTC

Roivant Sciences shares are higher in after-market trading, driven by a positive market reaction to the July Consumer Price Index report.

2026. aug. 11. 21:01 UTC

Roivant Sciences Ltd shares are lower in after-market hours, continuing recent declines amid broader market volatility linked to U.S.-Iran relations.

2026. aug. 10. 23:02 UTC

Roivant Sciences Ltd shares are higher in after-market hours, trading above their 20-day moving average and near the upper end of their one-month range.

2026. aug. 7. 20:02 UTC

Event
News

Roivant Sciences Ltd shares are higher as HC Wainwright maintains a Buy rating and raises the price target to $41 amid positive developments in its product pipeline.

2026. aug. 6. 20:03 UTC

News
Event

Roivant Sciences reported a net loss of $290.6 million in Q1, exceeding expectations. Shares are higher despite pulling back from session highs earlier.

2026. aug. 5. 22:01 UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting notable activity following Wednesday's close. The stock is positioned above its 20-day moving average.

2026. aug. 4. 20:02 UTC

Roivant Sciences is rising amid positive market sentiment and declining crude oil prices. Remarks from Treasury Secretary Scott Bessent also support the favorable environment.

2026. aug. 3. 20:06 UTC

Roivant Sciences Ltd shares are declining today, breaking a trend of higher closes. Broader market indices are up, but no specific news explains the drop.

Társak összehasonlítása

Árváltozás

Roivant Sciences Ltd Előrejelzés

Célár

By TipRanks

11.62% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 45.563 USD  11.62%

Magas 55 USD

Alacsony 37.5 USD

8 Wall Street elemző 12 hónapos célárain alapulva a(z)Roivant Sciences Ltd termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

8 ratings

7

Vétel

1

Tartás

0

Eladás

Hangulat

By Acuity

112 / 339 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
help-icon Live chat